COMP Report: CPQR technical quality control guidelines for CyberKnife® Technology.

The Canadian Organization of Medical Physicists (COMP), in close partnership with the Canadian Partnership for Quality Radiotherapy (CPQR) has developed a series of Technical Quality Control (TQC) guidelines for radiation treatment equipment. These guidelines outline the performance objectives that equipment should meet in order to ensure an acceptable level of radiation treatment quality. This particular TQC contains detailed performance objectives and safety criteria for CyberKnife® Technology. The quality control recommendations in this document are based upon previously published guidelines and the collective experience of all Canadian sites using this technology. This TQC guideline has been field tested at the newest Canadian CyberKnife installation site and includes recommendations for quality control of the Iris™ and InCise™ MLC collimation systems.

Stereotactic Ablative Radiation Therapy for the Treatment of Upper Urinary Tract Urothelial Carcinoma.

PURPOSE: Urothelial carcinomas (UCs), also known as transitional cell carcinomas, account for the majority of upper urinary tract tumors. The gold-standard therapy for operable patients with localized disease is radical nephroureterectomy. However, some patients are not surgical candidates. Data on the use of modern radiation therapy for upper urinary tract UC (UTUC) are scarce. The purpose of this study was to assess the safety and efficacy of SABR in UTUC. METHODS AND MATERIALS: This retrospective study included all patients with UTUC treated with SABR at one institution. Charts were reviewed to evaluate renal function and the development of toxicity using Common Terminology Criteria for Adverse Events, version 3.0. Tumor response on follow-up imaging with computed tomography or magnetic resonance imaging scans was assessed using the Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: A total of 16 patients (7 patients with UC at the ureter and 9 at the renal pelvis) were identified as treated with SABR. Of the 9 patients with renal pelvis UC, 4 had a previous history of bladder cancer. At the time of treatment, the median age was 85 years (range, 67-95 years). Most patients received 40 Gy in 8 fractions every second day. The median followup was 21 months (range, 3-110 months). Most patients maintained stable renal function, and only 2 patients developed worsening chronic kidney disease, but none required dialysis. Acutely, 4 patients developed grade 1 diarrhea, and 1 patient had new grade 1 hematuria. No chronic side effects were observed. One patient did not have follow-up imaging and was excluded from the tumor-response analysis. Two patients had a complete response of the treated lesion, 9 had a partial response, 2 had stable disease, and 2 had disease progression within the treatment field. CONCLUSIONS: This small case series suggests that SABR for UTUC is safe and well-tolerated, with good radiographic tumor response to ablative doses of radiation therapy.

Practical considerations for prostate hypofractionation in the developing world.

External beam radiotherapy is an effective curative treatment option for localized prostate cancer, the most common cancer in men worldwide. However, conventionally fractionated courses of curative external beam radiotherapy are usually 8-9 weeks long, resulting in a substantial burden to patients and the health-care system. This problem is exacerbated in low-income and middle-income countries where health-care resources might be scarce and patient funds limited. Trials have shown a clinical equipoise between hypofractionated schedules of radiotherapy and conventionally fractionated treatments, with the advantage of drastically shortening treatment durations with the use of hypofractionation. The hypofractionated schedules are supported by modern consensus guidelines for implementation in clinical practice. Furthermore, several economic evaluations have shown improved cost effectiveness of hypofractionated therapy compared with conventional schedules. However, these techniques demand complex infrastructure and advanced personnel training. Thus, a number of practical considerations must be borne in mind when implementing hypofractionation in low-income and middle-income countries, but the potential gain in the treatment of this patient population is substantial.

Stereotactic radiotherapy as an alternative to plaque brachytherapy in retinoblastoma.

Radioactive plaque brachytherapy has an established role for selected patients with retinoblastoma. Newer non-invasive radiotherapy techniques such as stereotactic conformal radiotherapy (SCR) that uses highly accurate positioning to deliver treatment with small beams may be an interesting alternative to brachytherapy. We report a case treated with SCR and compare the dosimetry with that achievable with brachytherapy. With advantages and disadvantages to both, SCR should more often be considered in the management of RB because of the more homogeneous dose within the target volume and similar or lower doses to surrounding normal tissues.

An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10,327 pretreatment daily ultrasound localizations.

INTRODUCTION: We have assessed the planning target volume (PTV) margins required for adequate treatment of the prostate in the absence of daily localization imaging based on the statistical analysis of a large data set obtained from 5 years of use of a two-dimensional ultrasound pretreatment localization device. METHODS AND MATERIALS: Data from 387 prostate patients were analyzed retrospectively. Every patient in the study received daily pretreatment localization resulting in a total of 10,327 localizations, each comprising an isocenter displacement in three directions: anteroposterior, right-left lateral, and superior-inferior. The mean displacement for each direction for each patient was computed from daily treatment records, and a mean of the means was used in the analysis. RESULTS: The mean displacements required to shift the target to the required position were 6.1 mm posterior (4.4 mm SD), 2.1 mm superior (4.5 mm SD), and 0.5 mm right (3.6 mm SD). The 6.1-mm shift posterior is indicative of a systematic uncertainty. Differences in planning conditions between the computed tomography simulation and the treatment room may account for this discrepancy. CONCLUSION: Our study has revealed systematic intertreatment uncertainties that would have required a nonuniform PTV margin ranging in dimensions between 2.7 mm anterior, 14.9 mm posterior, 7.7 mm right, 6.7 mm left, 11 mm superior, and 7 mm inferior to encompass the prostate for 95% of our sample if the ultrasound localization system were not used. In the absence of systematic uncertainties, a uniform PTV margin of 9 mm would suffice.

Accelerated radiotherapy with simultaneous integrated boost fractionation and intensity-modulated radiotherapy for advanced head and neck cancer.

OBJECTIVE: To determine the feasibility and toxicity profile of accelerated radiotherapy with a simultaneous integrated boost fractionation scheme with intensity-modulated radiotherapy (SIB-IMRT) with or without chemotherapy. STUDY DESIGN AND SETTING: Forty-nine patients with advanced head and neck cancer underwent SIB-IMRT. Concomitant chemotherapy was administered in 29 patients. RESULTS: Grade 3 acute toxicities included 55% mucositis, 20% odynophagia, 12% nausea, 18% hematologic, and 8% skin. There were no grade 4 toxicities or treatment-related deaths. With a median follow-up of 25 months, locoregional control was 83%, and overall survival was 80%. Of patients with grade 3 late toxicities, two patients (4% of the total) required a permanent percutaneous endoscopic gastrostomy tube, and osteonecrosis occurred in one patient (2% of the total). CONCLUSIONS: SIB-IMRT is a feasible technique that shortens the overall treatment time in the radical treatment of patients with advanced head and neck cancer while maintaining acceptable rates of acute toxicity in this study. Although the results are promising, this approach should be considered only in the setting of a clinical trial.

Development of a Monte Carlo model for the Brainlab microMLC.

Stereotactic radiosurgery with several static conformal beams shaped by a micro multileaf collimator (microMLC) is used to treat small irregularly shaped brain lesions. Our goal is to perform Monte Carlo calculations of dose distributions for certain treatment plans as a verification tool. A dedicated microMLC component module for the BEAMnrc code was developed as part of this project and was incorporated in a model of the Varian CL2300 linear accelerator 6 MV photon beam. As an initial validation of the code, the leaf geometry was visualized by tracing particles through the component module and recording their position each time a leaf boundary was crossed. The leaf dimensions were measured and the leaf material density and interleaf air gap were chosen to match the simulated leaf leakage profiles with film measurements in a solid water phantom. A comparison between Monte Carlo calculations and measurements (diode, radiographic film) was performed for square and irregularly shaped fields incident on flat and homogeneous water phantoms. Results show that Monte Carlo calculations agree with measured dose distributions to within 2% and/or 1 mm except for field size smaller than 1.2 cm diameter where agreement is within 5% due to uncertainties in measured output factors.

Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.

INTRODUCTION: From a radiation treatment planner perspective, in the treatment of prostate cancer, inverse-planned intensity-modulated radiation therapy (IMRT) differs considerably from conventional, conformal, and forward-planned IMRT. In this work we aim to discuss the rationale behind the use of inverse-planned IMRT for the treatment of prostate cancer, as well as some of the practical aspects, including the differences in planning strategies, dose fractionation and issues in plan evaluation. DISCUSSION: The primary motivation behind the use of inverse-planned IMRT for prostate cancer radiotherapy is to attempt further dose escalation while maintaining critical structure and healthy tissue sparing at an acceptable level. The sparing of normal tissues is largely dependent on the size of the planning target volume (PTV) defined, and if the PTV overlaps critical structures. Depending on how the PTV is defined it may be impossible to achieve the desired healthy tissue sparing even with IMRT. A second role for the use of IMRT in the treatment of prostate cancer may be to conform the isodose distribution to a complex PTV, such as one that includes the seminal vesicles or the pelvic lymph nodes in the treatment volume. Finally, inverse planned IMRT may be useful in the planning and delivery of simultaneous integrated boosts where different parts of the target structures receive different daily doses. This again has applications for the simultaneous treatment of pelvic lymph nodes with the prostate treatment volume, and presents interesting opportunities for hypo-fractionation. All of these options of course require careful plan evaluation with respect to isodose distributions and dose-volume constraints as well as the radiobiological consequences of using unconventional fractionation. CONCLUSION: IMRT seems to be the most effective modality for treating complex target geometries and for delivering simultaneous integrated boosts. In particular for prostate cancer, the simultaneous treatment of the prostate and pelvic lymph nodes lends itself perfectly to IMRT, allowing the prostate to receive a higher daily dose per fraction, as well as minimizing the amount of small bowel in the field, while at the same time sparing the rectum and bladder adequately. Inverse-planned IMRT is, however, a complex procedure, and to safely implement it, an extensive patient- and machine-specific quality assurance program is required.

The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.

PURPOSE: Despite major advances in treatment modalities, the prognosis of patients with glioblastoma multiforme (GBM) remains poor. Exploring hypofractionated regimens to replace the standard 6-week radiotherapy schedule is an attractive strategy as an attempt to prevent accelerated tumor cell repopulation. There is equally interest in dose escalation to the gross tumor volume where the majority of failures occur. We report our preliminary results using hypofractionated intensity-modulated accelerated radiotherapy regimen in the treatment of patients with GBM. METHODS AND MATERIALS: Between July 1998 and December 2001, 25 patients with histologically proven diagnosis of GBM, Karnofsky performance status > or =60, and a postoperative tumor volume < or =110 cm3 were treated with a hypofractionated accelerated course of radiotherapy. The gross tumor volume (GTV) was defined as the contrast-enhancing lesion on the postoperative MRI T1-weighted images with the latter fused with computed tomography images for treatment planning. The planning target volume was defined as GTV + 1.5-cm margin. Using forward-planning intensity modulation (step-and-shoot technique), 60 Gy in 20 daily fractions of 3 Gy each were given to the GTV, whereas the planning target volume received a minimum of 40 Gy in 20 fractions of 2 Gy each at its periphery. Treatments were delivered over a 4-week period using 5 daily fractions per week. Dose was prescribed at the isocenter (ICRU point). Three beam angles were used in all of the cases. RESULTS: Treatments were well tolerated. Acute toxicity was limited to increased brain edema during radiotherapy in 2 patients who were on tapering doses of corticosteroids. This was corrected by increasing the steroid dose. At a median follow-up of 8.8 months, no late toxicity was observed. One patient experienced visual loss at 9 months after completion of treatment. MRI suggested nonspecific changes to the optic chiasm. On review of the treatment plan, the total dose to the optic chiasm was confirmed to be equal to or less than 40 Gy in 20 fractions. When Radiation Therapy Oncology Group recursive partitioning analysis was used, 10 patients were class III-IV, and 15 patients were class V-VI. To date, 21 patients have had clinical and/or radiologic evidence of disease progression, and 16 patients have died. The median survival was 9.5 months (range: 2.8-22.9 months), the 1-year survival rate was 40%, and the median progression-free survival was 5.2 months (range: 1.9-12.8 months). CONCLUSION: This hypofractionated accelerated irradiation schedule using forward planning (step-and-shoot) hypofractionated, intensity-modulated accelerated radiotherapy is feasible and seems to be a safe treatment for patients with GBM. A 2-week reduction in the treatment time may be of valuable benefit for this group of patients. However, despite this accelerated regimen, no survival advantage has been observed.

Physical aspects of dynamic stereotactic radiosurgery with very small photon beams (1.5 and 3 mm in diameter).

Stereotactic radiosurgery is often used for treating functional disorders. For some of these disorders, the size of the target can be on the order of a millimeter and the radiation dose required for treatment on the order of 80 Gy. The very small radiation field and high prescribed dose present a difficult challenge in beam calibration, dose distribution calculation, and dose delivery. In this work the dose distribution for dynamic stereotactic radiosurgery, carried out with 1.5 and 3 mm circular fields, was studied. A 10 MV beam from a Clinac-18 linac (Varian, Palo Alto, CA) was used as the radiation source. The BEAM/EGS4 Monte Carlo code was used to model the treatment head of the machine along with the small-field collimators. The models were validated with the EGSnrc code, first through a calculation of percent depth doses (PDD) and dose profiles in a water phantom for the two small stationary circular beams and then through a comparison of the calculated with measured PDD and profile data. The three-dimensional (3-D) dose distributions for the dynamic rotation with the two small radiosurgical fields were calculated in a spherical water phantom using a modified version of the fast XVMC Monte Carlo code and the validated models of the machine. The dose distributions in a horizontal plane at the isocenter of the linac were measured with low-speed radiographic film. The maximum sizes of the Monte Carlo-calculated 50% isodose surfaces in this horizontal plane were 2.3 mm for the 1.5 mm diameter beam and 3.8 mm for the 3 mm diameter beam. The maximum discrepancies between the 50% isodose surface on the film and the 50% Monte Carlo-calculated isodose surfaces were 0.3 mm for both the 1.5 and 3 mm beams. In addition, the displacement of the delivered dose distributions with respect to the laser-defined isocenter of the machine was studied. The results showed that dynamic radiosurgery with very small beams has a potential for clinical use.

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiation therapy in the treatment of intermediate-risk prostate cancer - long term results.

PURPOSE: We present the long-term results of a cohort of patients with intermediate-risk prostate cancer (PC) treated with single-fraction high-dose-rate brachytherapy (HDRB) combined with hypofractionated external beam radiation therapy (HypoRT). METHODS AND MATERIALS: Patients were treated exclusively with HDRB and HypoRT. HDRB delivered a dose of 10 Gy to the prostate surface and HypoRT consisted of 50 Gy delivered in 20 daily fractions. The first 121 consecutive patients with a minimum of 2 years posttreatment follow-up were assessed for toxicity and disease control. RESULTS: The median follow-up was 65.2 months. No acute Grade III or higher toxicity was seen. Late Grade II gastrointestinal toxicity was seen in 9 patients (7.4%) and Grade III in 2 (1.6%). Late Grade III genitourinary toxicity was seen in 2 patients (1.6%). After a 24-month follow-up, a rebiopsy was offered to the first 58 consecutively treated patients, and 44 patients agreed with the procedure. Negative biopsies were found in 40 patients (91%). The 5-year biochemical relapse-free survival rate was 90.7% (95% CI, 84.5-96.9%), with 13 patients presenting biochemical failure. Among them, 9 were diagnosed with distant metastasis. Prostate cancer-specific and overall survival rates at 5 years were 100% and 98.8% (95% CI, 96.4-100%), respectively. CONCLUSION: The combination of HDRB and HypoRT is well tolerated, with acceptable toxicity rates. Furthermore, results from rebiopsies revealed an encouraging rate of local control. These results confirm that the use of conformal RT techniques, adapted to specific biological tumor characteristics, have the potential to improve the therapeutic ratio in intermediate-risk PC patients.

Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience.

PURPOSE: To report our experience with linear accelerator-based stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma. METHODS AND MATERIALS: We performed a retrospective review of 50 consecutive patients diagnosed with juxtapapillary choroidal melanoma and treated with linear accelerator-based stereotactic fractionated radiotherapy between April 2003 and December 2009. Patients with small to medium sized lesions (Collaborative Ocular Melanoma Study classification) located within 2 mm of the optic disc were included. The prescribed radiation dose was 60 Gy in 10 fractions. The primary endpoints included local control, enucleation-free survival, and complication rates. RESULTS: The median follow-up was 29 months (range, 1-77 months). There were 31 males and 29 females, with a median age of 69 years (range, 30-92 years). Eighty-four percent of the patients had medium sized lesions, and 16% of patients had small sized lesions. There were four cases of local progression (8%) and three enucleations (6%). Actuarial local control rates at 2 and 5 years were 93% and 86%, respectively. Actuarial enucleation-free survival rates at 2 and 5 years were 94% and 84%, respectively. Actuarial complication rates at 2 and 5 years were 33% and 88%, respectively, for radiation-induced retinopathy; 9.3% and 46.9%, respectively, for dry eye; 12% and 53%, respectively, for cataract; 30% and 90%, respectively, for visual loss [Snellen acuity (decimal equivalent), <0.1]; 11% and 54%, respectively, for optic neuropathy; and 18% and 38%, respectively, for neovascular glaucoma. CONCLUSIONS: Linear accelerator-based stereotactic fractionated radiotherapy using 60 Gy in 10 fractions is safe and has an acceptable toxicity profile. It has been shown to be an effective noninvasive treatment for juxtapapillary choroidal melanomas.

Prostate gland edema after single-fraction high-dose rate brachytherapy before external beam radiation therapy.

PURPOSE: High-dose rate brachytherapy (HDRB) is frequently used as a boost to external beam radiation therapy (EBRT) in prostate cancer patients. With the increasing use of small planning target volume margins in EBRT, prostatic edema induced by HDRB can be a contributing factor to geometric miss when HDRB is performed before or during EBRT. We assessed prostate gland volumetric change after single-fraction HDRB and its impact on definition of treatment volume for EBRT. METHODS AND MATERIALS: Thirty-one consecutive patients with intermediate-risk prostate cancer treated with single-fraction HDRB (10 Gy) combined with hypofractionated EBRT were analyzed. A second CT scan was performed 7 days after HDRB, and images were coregistered with the planning CT scan that contained the original clinical target volume (CTV). The post-HDRB prostate CTV volume was compared with the original CTV by a single observer. RESULTS: All patients presented volumetric variation. In most cases (68%), the prostate increased in volume, whereas it decreased in 32%. The mean prostatic volume was 42.2 cc before HDRB and 43.6 cc after HDRB, representing a mean volume difference of 3.4%, ranging from -14.2% to 23.8% (p=0.756). This difference is the result of mean changes of 0.6mm (-6.1 to 6.6) in the anterior-posterior, 0.5mm (-5.5 to 3.0) in the lateral, and 0.2mm (-5.0 to 5.0) in the superior-inferior axes. CONCLUSIONS: Although a nonsignificant volumetric change occurs after single-fraction HDRB, individual variations on specific axis could lead to important uncertainties during EBRT.